pharmaphorum

OCTOBER 21, 2021

Aduhelm is currently under review by the Center for Medicare and Medicaid Services (CMS), which isn’t due to deliver recommendations on reimbursement until next year – which Vounatsos said was delaying treatment for patients who might benefit from the drug.

Sales 121

Sales Doctors Doctor Gene Therapy 121

Rethinking Clinical Trials

JULY 19, 2023

That might be an important jumping point for the second leg of COORDINATE-Diabetes to answer questions such as: How do you get payers and Medicare to sustain these interventions? Tags #pctGR, @Collaboratory1 The post Grand Rounds July 14, 2023: Lessons From the COORDINATE-Diabetes Trial (Christopher B.

Trials 130

Trials Cardiology Medicine Nurses 130

pharmaphorum

MAY 10, 2022

The FDA awarded a fast-track designation to lecanemab in December and has also given the drug breakthrough tag as a treatment for early-stage Alzheimer’s, and Biogen and Eisai will be hoping the drug can sidestep the controversy that engulfed Aduhelm from the moment it was approved.

FDA Approval 40

FDA Approval Trials Clinical Trials Clinical Trials 40

pharmaphorum

NOVEMBER 24, 2021

Earlier this month, Massachusetts became the first US state to reSET and reSET-O for Medicare patients, and Pear says more than 30 organizations now provide access to the DTx products by either listing on a formulary as a covered benefit or purchasing courses in bulk. Photo by thom masat on Unsplash.

Production 58

Production Development Trials 58

XTalks

JULY 12, 2021

This would be a huge burden on Medicare, while private insurers would be shying away from it. On the other hand, Biogen is being aggressively questioned over its tacking on of such a hefty price tag for the drug. All of this for a drug that has shown questionable clinical benefits, critics say.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

pharmaphorum

DECEMBER 17, 2021

Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.

Trials 52

Trials Sales Marketing FDA Approval 52

XTalks

JUNE 9, 2021

Aducanumab Controversy and Price Tag. Industry experts say that while 85 percent to 90 percent of patients in the US are eligible to be covered for the drug by Medicare, it is likely that other insurers, and even Medicare, will limit their coverage to the type of patients who participated in the trial. Clinical Evidence.

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

World of DTC Marketing

DECEMBER 13, 2021

As cancer survival rates rise, so do the price tags of life-saving treatments. Monthly drugs costs may reach $100,000, causing many Americans to struggle with the physical and emotional effects of high out-of-pocket medical costs. Even worse, others are completely priced out of the hope for a cure.

Drugs 55

Drugs FDA Approval Medicine Containment 55

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a 5.1%

Drugs 264

Drugs Manufacturing Hormones Contract Manufacturing 264

Pharmaceutical Technology

NOVEMBER 30, 2022

The company’s weight loss drug Saxenda (liraglutide) won an approval for chronic weight management in December 2014, and Wegovy (semaglude) got the same tag in 2021. Novo Nordisk is another company leading the charge in this field. In a Phase II study, CagriSema achieved a numerically higher body weight reduction of 15.6% compared to a 5.1%

Drugs 246

Drugs Manufacturing Hormones Contract Manufacturing 246

The Pharma Data

MAY 4, 2021

healthcare reform or legislation or any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented; U.S. in December 2019; and. Amy Rose 212.733.7410. Bryan Dunn 212.733.8917.

Vaccination 40

Vaccination Vaccine Production Sales 40

World of DTC Marketing

JUNE 16, 2021

There are proposals to allow the federal government to negotiate with drug companies to get a lower price on medications that would apply to both Medicare and private insurance and the KFF Health Tracking Poll finds majorities support this proposal, regardless of party identification.

Drugs 180

Drugs Branding Medicine Insulin 180

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

HR 40

HR Marketing Doctors Doctor 40